로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Licensing > BNO202202

c-Met/AXL inhibitor

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: c-Met/AXL inhibitor
    Indications: Gastric cancer, solid tumor
    Research phase: IND Approval
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA: High selectivity of inhibiting dual c-Met and AXL



    Clear MoA



    2. Significant preclinical efficacy and less toxic & side effects.


    1) Low dose efficacy supior to positive control Eli Lilly ‘s LY2801653


    2) Tumor shrinkage in a highly selective c-Met-resistant gastric cancer model after treatment


    3. Global competitiveness:


    BIC Potential.There is no drug targeting high expression of c-Met in gastric cancer yet. It is expected to be the first drug targeting high expression of c-Met in gastric cancer.



    4. Good market potential:



    It is estimated that there will be 525,000 gastric cancer patients in 2024, and the gastric cancer drug market will reach 43.2 billion yuan.

  • Project Introduction

    1. Asset type: c-Met/AXL inhibitor

    2. Indication: Gastric cancer, solid tumor

    3. Research phase: IND Approval

    4. Cooperation demands:   License-out or co-development

    5. Research progress:

    1.Completed preclinical development and obtained IND approval from NMPA.

    2.In vitro experiments, the phosphorylation level of target protein c-Met and downstream proteins AKT and ERK was significantly inhibited.

    3.The selective inhibitor showed better tumor suppressing effect than the same dose of LY2801 653 in three gastric cancers with high expression of c-Met.

    4.Completed safety profile.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments